Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]SDM-16
- Development stage
- Preclinical
- Lead developer
- Yale University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]SDM-16 is a novel, high-affinity, and metabolically stable positron emission tomography (PET) radiotracer designed for imaging synaptic vesicle glycoprotein 2A (SV2A) in the central nervous system. Developed by researchers at the Yale School of Medicine in collaboration with AbbVie, [18F]SDM-16 is based on the molecular scaffold of UCB-A and serves as a fluorine-18 labeled alternative to carbon-11 labeled tracers like [11C]UCB-J. Due to its longer half-life (approximately 109.8 minutes) and superior in vivo metabolic stability compared to other SV2A tracers, [18F]SDM-16 allows for the reliable and sensitive quantification of synaptic density. It is primarily investigated for its utility in visualizing and tracking synapse loss in neurodegenerative disorders, such as Alzheimer's disease.
- Other names
- (R)-4-(3-fluoro-5-(fluoro-18F)phenyl)-1-((2-methyl-1H-imidazol-1-yl)methyl)pyrrolidin-2-one(R)-[18F]SDM-1618F-SDM16SDM16SDM-16SDM 16[18F]SDM16
02
Targets
SV2A (Synaptic vesicle glycoprotein 2A)
Beyond the preview
Go deeper on [18F]SDM-16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]SDM-16.